Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-((1-(6-(trifluoromethyl)-1h-benzo(d)imidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyrdin-2(1h)-one
2. Bgb-283
3. Lifrafenib
1. Lifirafenib
2. Bgb-283
3. 1446090-77-2
4. 1446090-79-4
5. Bgb283
6. Lifirafenib [usan]
7. 5-(((1r,1as,6br)-1-(6-(trifluoromethyl)-1h-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1h)-one
8. Bgb 283
9. 8762xzs5zf
10. 5-(((1r,1as,6br)-1-(6-(trifluoromethyl)-1h-benzimidazol-2-yl)-1a,6b-dihydro-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1h-1,8-naphthyridin-2-one
11. 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one
12. 1,8-naphthyridin-2(1h)-one, 5-(((1r,1as,6br)-1a,6b-dihydro-1-(6-(trifluoromethyl)-1h-benzimidazol-2-yl)-1h-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-
13. 5-({(1r,1as,6br)-1-[5-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1h)-one
14. Compound 2.2b
15. 5-{{(1r,1as,6br)-1-[5-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl}oxy}-3,4-dihydro-1,8-naphthyridin-2(1h)-one
16. Lifirafenib [inn]
17. Lifirafenib (usan/inn)
18. Unii-8762xzs5zf
19. Bgb-283;beigene-283
20. Lifirafenib [who-dd]
21. Gtpl8958
22. Chembl4209157
23. Schembl15085288
24. Bdbm372968
25. Ex-a1473
26. Us9895376, Compound 2.2b
27. Whc09077
28. Whc09079
29. Lifirafenib;bgb-283;beigene-283
30. Bdbm50453816
31. Who 10554
32. Zinc68764621
33. Cs-6308
34. Db14773
35. Ac-35880
36. Ac-36373
37. Hy-18957
38. D11410
39. A900647
40. Q27075193
41. 3k3
| Molecular Weight | 478.4 g/mol |
|---|---|
| Molecular Formula | C25H17F3N4O3 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 478.12527490 g/mol |
| Monoisotopic Mass | 478.12527490 g/mol |
| Topological Polar Surface Area | 89.1 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 845 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Lifirafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lifirafenib, including repackagers and relabelers. The FDA regulates Lifirafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lifirafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lifirafenib supplier is an individual or a company that provides Lifirafenib active pharmaceutical ingredient (API) or Lifirafenib finished formulations upon request. The Lifirafenib suppliers may include Lifirafenib API manufacturers, exporters, distributors and traders.
Lifirafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lifirafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lifirafenib GMP manufacturer or Lifirafenib GMP API supplier for your needs.
A Lifirafenib CoA (Certificate of Analysis) is a formal document that attests to Lifirafenib's compliance with Lifirafenib specifications and serves as a tool for batch-level quality control.
Lifirafenib CoA mostly includes findings from lab analyses of a specific batch. For each Lifirafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lifirafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lifirafenib EP), Lifirafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lifirafenib USP).
LOOKING FOR A SUPPLIER?
